| __timestamp | Agios Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 55430000 |
| Thursday, January 1, 2015 | 141827000 | 65510000 |
| Friday, January 1, 2016 | 220163000 | 71160000 |
| Sunday, January 1, 2017 | 292681000 | 70644000 |
| Monday, January 1, 2018 | 341324000 | 70418000 |
| Tuesday, January 1, 2019 | 410894000 | 63238000 |
| Wednesday, January 1, 2020 | 367470000 | 59777000 |
| Friday, January 1, 2021 | 256973000 | 60152000 |
| Saturday, January 1, 2022 | 279910000 | 54540000 |
| Sunday, January 1, 2023 | 288903000 | 52243000 |
| Monday, January 1, 2024 | 301286000 | 64536000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Agios Pharmaceuticals, Inc. has consistently outpaced Taro Pharmaceutical Industries Ltd. in R&D investment. From 2014 to 2023, Agios's R&D expenses surged by approximately 188%, peaking in 2019. In contrast, Taro's R&D spending remained relatively stable, with a modest increase of around 17% over the same period.
Agios's aggressive investment strategy highlights its commitment to pioneering new treatments, while Taro's steady approach reflects a focus on optimizing existing products. Notably, Agios's R&D expenses in 2019 were nearly six times higher than Taro's, underscoring its ambitious growth trajectory. However, the data for 2024 is incomplete, suggesting a potential shift in trends. As the pharmaceutical industry evolves, these R&D strategies will play a pivotal role in shaping the future of healthcare.
Comparing Innovation Spending: Pfizer Inc. and Agios Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Taro Pharmaceutical Industries Ltd.
Regeneron Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.: Who Invests More in Innovation?
R&D Spending Showdown: Biogen Inc. vs Taro Pharmaceutical Industries Ltd.
Analyzing R&D Budgets: Alkermes plc vs Agios Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CymaBay Therapeutics, Inc. and Agios Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for CRISPR Therapeutics AG and Taro Pharmaceutical Industries Ltd.
Who Prioritizes Innovation? R&D Spending Compared for PTC Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.
Mesoblast Limited or Agios Pharmaceuticals, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Viridian Therapeutics, Inc.: Who Invests More in Innovation?